about akston
process
pipeline
news
careers
contact
NEWS
12 April 2022
Akston Biosciences CEO to Present at the World Vaccine Congress
7 April 2022
COVID-19 vaccine: Akston Biosciences doses first volunteers in Phase II/III trial
7 April 2022
Akston Biosciences Doses First Volunteers in Phase II/III Clinical Trial of Low Cost, Shelf Stable COVID-19 Vaccine
31 March 2022
Akston Biosciences Receives Regulatory Approval for Phase II Clinical Trial for Shelf-Stable COVID-19 Vaccine Booster
18 March 2022
Will the Second Wave of COVID-19 Vaccines Have the Improved Properties Needed to End the Pandemic?
17 March 2022
Akston Biosciences and Biolexis Collaborate to Launch a Room Temperature Stable 2nd Generation COVID-19 Vaccine in 130+ Countries
17 March 2022
Stelis Licenses Akston’s AKS-452 Thermostable Protein Subunit COVID Vax
17 March 2022
2nd Generation COVID-19 Vaccine Available in 130+ Countries
17 March 2022
Akston Biosciences and Biolexis Collaborate to Launch a Room Temperature Stable 2nd Generation COVID-19 Vaccine in 130+ Countries
23 February 2022
Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452
1
4
5
6
11
